Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis |
| |
| Authors: | H. Tsukada T. Hirose A. Yokoyama Y. Kurita |
| |
| Affiliation: | 1. Department of Epidemiology, Office of the Chief Quality Officer, Baylor Scott & White Health, Dallas, Texas;2. Department of Cardiothoracic Surgery, Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas;3. Department of Cardiology, Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas;2. Department of Surgery, Duke University Medical Center, Durham, NC;3. Department of Anesthesiology, Perioperative, and Pain Medicine, Harvard Medical School, Boston, MA;1. Department of Urology, Keio University School of Medicine, Tokyo, Japan;2. Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan;1. Department of Cardiothoracic Surgery, St Vincent''s Hospital Melbourne, Fitzroy, Victoria, Australia;2. Department of Surgery, Austin Hospital, Heidelberg, Victoria, Australia;3. Department of Epidemiology and Preventative Medicine, Monash University, Prahran, Victoria, Australia;4. Department of Surgery (MMC), Monash University, Clayton, Victoria, Australia;5. Department of Cardiothoracic Surgery, Monash Medical Centre, Clayton, Victoria, Australia;6. Cabrini Medical Centre, Malvern, Victoria, Australia;7. University of Melbourne, Department of Surgery, St Vincent''s Hospital Melbourne, Fitzroy, Victoria, Australia |
| |
| Abstract: | The role of 5-hydroxytryptamine3 (HT3) antagonists in the treatment of delayed emesis is still controversial. To evaluate whether 5-HT3 antagonists can add to the efficacy of corticosteroids in controlling delayed emesis, we performed a randomised, prospective, open study comparing ondansetron plus dexamethasone with dexamethasone alone in cisplatin-treated patients. 149 cisplatin-naïve patients with lung cancer received at least 60 mg/m2 of cisplatin and were treated with dexamethasone 32 mg intravenously (i.v.) and granisetron 3 mg i.v. on day 1. Patients were randomly assigned to receive either dexamethasone 16 mg i.v. alone (arm A) or dexamethasone plus ondansetron 8 mg daily (arm B) on days 2–4. None of the efficacy variables related to control of delayed emesis differed significantly between the two arms. In conclusion, there does not appear to be sufficient evidence to support the prolonged use of 5-HT3 receptor antagonists after 24 h of cisplatin-containing chemotherapy. |
| |
| Keywords: | Delayed emesis Antiemetics Cisplatin Ondansetron Dexamethasone 5-HT3-receptor antagonists |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
